Potential Therapeutic Targets in Alveolar Soft Part Sarcoma – by Dr. Dina Lev

Dr. Dina Lev, from the Cancer Biology and the Sarcoma Research Center at the University of Texas M. D. Anderson has published a new study on Alveolar Soft Part Sarcoma. Her study appeared in the Journal of Histopathology. The aim of this study was to evaluate the expression of potential gene therapeutic targets in a cohort of ASPS tumor samples. Dr. Lev analyzed 26 primary and metastatic ASPS tumor samples. Her study confirmes that activation of c-Met and its downstream effectors are prominent in ASPS. She also identified limited EGFR (Epidermal Growth Factor Receptor) expression in few tumors as well. VEGF (Vascular endothelial growth factor), was expressed in all the tumors to varying degrees. Dr. Lev concluded that there is a crucial need for better anti-ASPS therapies. Her study demonstrated that combination therapies against few activated pathways in ASPS could be the right concept for the treatment of Alveolar Soft Part Sarcoma.


Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)